Abstract:MiR-525-5p functions as an oncomiRNA or tumor suppressor, and has been reported in various cancer types, including laryngeal squamous cell carcinoma, glioma, breast cancer, and cervical cancer. However, the biological functions and precise mechanisms of miR-525-5p remain unclarified in Burkitt’s lymphoma (BL). This study aimed to explore the roles of miR-525-5p in BL, with the goal of ascertaining its regulatory effects on the nuclear factor-kappaB (NF-κB) signaling pathway by targeting Myeloid differentiation factor 88 (MyD88). The expression levels of miR-525-5p and MyD88 were measured by quantitative real-time PCR and immunohistochemical staining, respectively. The effects of miR-525-5p overexpression on BL cell proliferation, colony-forming, and migration were evaluated by cell counting kit-8, soft agar colony-forming, and transwell assays, while cell cycle and cell apoptosis were analyzed by flow cytometry. Possible interactions between miR-525-5p and MyD88 was examined via luciferase reporter assay. The expression of MyD88 and NF-κB signaling pathway-related proteins, including p65, p-p65, IκBa, and p-ΙκBa was determined by western blotting. BL cells overexpressing miR-525-5p were treated with phorbol 12-myristate 13-acetate (PMA), and Hoechst 33258 staining and Calcein AM/EthD-I staining were used to analyze the changes in chemotherapy sensitivity of BL cells to doxorubicin (DOX). Compared with reactive lymphoid hyperplasia, miR-525-5p was dramatically downregulated in BL tissues, while the rate of MyD88 protein positivity was significantly increased. Upregulation of miR-525-5p suppressed cell proliferation, colony-forming, and migration, induced cell cycle arrest and apoptosis, and enhanced the chemosensitivity to DOX in BL cells. MiR-525-5p targeted MyD88 to inhibit the activation of NF-κB signaling pathway. PMA treatment reactivated the NF-κB pathway and reversed apoptosis mediated by miR-525-5p overexpression. These findings revealed that miR-525-5p acts as a tumor suppressor, targeting MyD88 to modulate proliferation, cell cycle progression, and apoptosis in BL cells by regulation of NF-κB signaling pathway.

Expression of MiR-296-5p in Diffuse Large B-Cell Lymphoma and Its Influence on Biological Behavior of Tumor Cells

[Expression of MiRNA-21 in Diffuse Large B Cell Lymphoma and Its Significance].

Comprehensive analysis of differentially expressed profiles of lncRNAs and mRNAs reveals ceRNA networks in the transformation of diffuse large B-cell lymphoma.

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

MiR-525-5p Modulates Cell Proliferation, Cell Cycle, and Apoptosis in Burkitt’s Lymphoma by Targeting MyD88 and Regulating the NF-κB Signaling Pathway

Clinical and Prognostic Significance of Mir-155 and Mir-146A Expression Levels in Formalin-Fixed/paraffin-embedded Tissue of Patients with Diffuse Large B-cell Lymphoma.

Inhibition Of Mir-21 Induces Biological And Behavioral Alterations In Diffuse Large B-Cell Lymphoma

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma

MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8+ T lymphocytes in human diffuse large B cell lymphoma

Expression of miR-224 in diffuse large B cell lymphoma and its clinical significance]

MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Deregulated Expression of Mir-224 and Its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP.

LncRNA SNHG8 Promotes Proliferation and Inhibits Apoptosis of Diffuse Large B-Cell Lymphoma via Sponging miR-335-5p

Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC

Aberrant Microrna Expression in Chinese Patients with Chronic Lymphocytic Leukemia.

Global Microrna Expression Profiling Uncovers Molecular Markers for Classification and Prognosis in Aggressive B-cell Lymphoma.

Serum Microrna Prognostic Model and Underlying Immune Alterations in Diffuse Large B Cell Lymphoma

Mir-181A/b Significantly Enhances Drug Sensitivity in Chronic Lymphocytic Leukemia Cells Via Targeting Multiple Anti-Apoptosis Genes.

Low Expression of Microrna-146B-5p and Microrna-320D Predicts Poor Outcome of Large B-cell Lymphoma Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

MicroRNA-204 Inhibits Expression of B Cell Lymphoma-2 in Non-Small Ceil Lung Cancer and Regulate Cell Biological Behaviors

MYC-dependent MiR-7-5p regulated apoptosis and autophagy in diffuse large B cell lymphoma by targeting AMBRA1